The current nonsurgical treatment options for men with Peyronie's disease is reviewed. The treatments currently employed and published in the English literature are discussed. A wide variety of nonsurgical treatment options are available to the practicing physician, including oral and topical medications, intralesional injection therapy, as well as employing external energy sources to drive medicine into the tunica albuginea by iontophoresis or direct stimulation of plaque change by shock wave therapy. Nonsurgical treatment of Peyronie's disease clearly has a place in the armamentarium of the practicing urologist. Oral therapy appears to have little therapeutic benefit. Injection and topical approaches deserve further attention. Yet, no single treatment stands out as the most effective remedy for all men with Peyronie's disease. Further controlled, large-scale studies are necessary to establish the benefits of these nonsurgical approaches. In the meantime, combination therapy appears to make sense in the nonsurgical treatment of men with Peyronie's disease.
In spite of various treatment options, Peyronie's disease remains a therapeutic dilemma for the practicing urologist. de la Peyronie advocated use of Barege spa water and mercurial ointments. In the 1800s, iodine, arsenic, and camphor were used. Throughout the years, different modes of energy transfer have been used including orthovoltage radiation, ultrasound, short-wave diathermy, and laser therapy. [1] [2] [3] None of these methods have found wide acceptance in the US and are not recommended at this time. The following discussion will review current treatment options based primarily upon experiences reported in the English literature. Unfortunately, most studies are compromised by poorly characterized subjects, limited numbers of patients, short follow-up times, no placebo or control groups, and little objective measure of change.
Oral therapy
The use of oral agents for the treatment of Peyronie's disease began in 1948. Scott and Scardino 4 reported on treatment of 23 patients with vitamin E, a tocopherol with antioxidant properties. The proposed dose was 200-300 mg per day. Based on changes in pain, plaque size, and angulation, they reported a beneficial effect in 11 patients, some improvement in 10, and no change in two patients. The study did not compare the effect of the treatment with the natural history of the disease. Use of vitamin E continued and, over time, became widely accepted because of its mild side-effect profile and low cost. Several studies have claimed favorable outcomes with vitamin E; however, the majority did not compare the outcomes with the natural history of the disease or a placebo controlled group. In 1990, Gelbard et al 5 compared the effects of the vitamin E treatment and natural progression of the Peyronie's disease. They described 27 patients who received no treatment and 59 patients who were taking vitamin E. They noted no significant differences between the two groups with respect to pain, bend, ability for intercourse, and over-all perception of disease progression. At this time, vitamin E continues to be the primary mode of oral treatment despite the lack of a controlled study showing its benefits.
In 1959, Zarafonetis and Horrax 6 studied potassium aminobenzoate (Potaba s ) as a systemic therapy agent. This substance is classified as 'possibly effective' by the Food and Drug Administration for the treatment of Peyronie's disease, scleroderma, dermatomyositis, linear scleroderma, and pemfigus.
One of the most extensive reviews of this therapy is a summary of 214 European urologists' experience with 2653 patients on Potaba. 7 The treatment was considered unsuccessful in 42.7% of the cases and successful in 57.3%, with complete resolution in 9.3%. The mechanism of action is not well understood. It has been suggested that Potaba increases utilization of oxygen by tissues and increases activity of monoamine oxidase, which decreases concentration of serotonin, a substance thought to contribute to fibrogenesis. Carson reported a retrospective review of 32 patients treated for at least 3 months with 12 g of Potaba powder daily and followed for 8-24 months. Subjective symptoms analysis demonstrated improvement in penile discomfort in eight of 18 (44%), decreased plaque size in 18 of 32 (56%), and improvement in penile angulation in 18 of 31 (58%) patients. Complete resolution of angulation was reported in eight of 31 (26%) patients. Carson 8 suggested that a prospective, double-blind, multicenter study with objective criteria was needed to control for the natural history of spontaneous resolution of Peyronie's disease symptomatology and to confirm the role of Potaba in the treatment of Peyronie's disease.
At the 1999 American Urological Association Annual meeting, Weidner et al 9 reported on 75 men who underwent a randomized prospective double-blind trial of Potaba 3 g q.i.d. for 1 y vs an oral placebo. In this well-conceived and important trial, no significant difference was seen with respect to improvement of curvature or pain between the two groups. The only parameter showing a statistically significant improvement was decrease in plaque size for the Potaba group. Unfortunately, a reduction in plaque size does not correlate with improvement of the most important parameter of curvature. Based upon these modest results, unsubstantiated mode of action, its relatively high cost, and side effects including gastrointestinal intolerance, which often results in noncompliance, enthusiasm for the use of Potaba is cautiously guarded. Ralph et al 10 described their experience with oral tamoxifen in 1992. It has been suggested that tamoxifen inhibits the release of transforming growth factor-beta (TGF-b) from fibroblasts.
11 TGFb has been shown to play a central role in regulating immune response, inflammation, and tissue repair by activating macrophages and T lymphocytes. Tamoxifen results in a reduced inflammatory response and, therefore, diminished angiogenesis and fibrogenesis. 12 Their preliminary study showed encouraging results in patients with recently (less than 4 months) acquired Peyronie's disease. Their regimen included 20 mg of tamoxifen twice a day for 3 months. A total of 80% of patients reported an improvement in pain, 35% showed improvement in deformity, and 34% experienced plaque shrinkage. Importantly, the most recently published report of a controlled trial of oral tamoxifen (20 mg b.i.d.) vs placebo demonstrated no therapeutic advantage to tamoxifen and several men reported scalp hair loss. 13 Like many of the newer treatment options, tamoxifen is difficult to recommend given the results of one of the few placebo-controlled trials in this field as well as the absence of larger longterm trials.
Oral colchicine therapy was first reported in a noncontrolled study by Akkus et al.
14 This agent is known to induce collagenase activity and decrease collagen synthesis. [15] [16] [17] Colchicine acts in four ways. It binds to tubulin and causes it to depolymerize and, subsequently, inhibits mobility and adhesion of leukocytes. It inhibits cell mitosis by disrupting the spindle fibers. It also blocks the lipoxygenase pathway or arachidonic acid metabolism, thus diminishing chemotaxis and inflammatory response. Lastly, it interferes with transcellular movement of protocollagen. Akkus et al recommended an initial dose of 0.6-1.2 mg daily during the first week of treatment followed by a gradual increase to 2.4 mg over 3-5 months. Although not qualified further, penile curvature was slightly improved in two (11%) and markedly improved in five (26%) of the 19 cases. Seven of nine patients with painful erections reported significant relief. Palpable plaque disappeared in two and decreased in 10 patients. The investigators also performed ultrasound on five patients and described a decrease of approximately 50% in plaque size. However, the authors pointed out that a double-blind study is needed to better evaluate the usefulness of this medication. The primary reported side effect of colchicine is gastrointestinal upset with diarrhea. A subsequent noncontrolled study of colchicine response was performed in a group of patients with acute Peyronie's disease by Kadioglu et al. 18 They examined the results of 1 mg of colchicine twice per day for 2-6 months with a mean follow-up of 11 months. The pain was diminished in 95%, curvature was measured and noted to be diminished in 30%, but worse in 21.7% of subjects. Patients with less severe degrees of deformity and plaque size did better overall in this study and only one patient withdrew secondary to severe diarrhea.
The oral supplement carnitine has been reported in two studies from the same group. 19, 20 The rationale for the use of this agent in patients with Peyronie's disease remains unclear, but it was suggested that this agent restores cells when damaged by inflammation or ischemia and this may be due to inhibition of the toxic coenzyme acetyl coenzyme A. In the first study, 48 men were randomized to receive oral acetyl-l-carnitine vs tamoxifen. Evaluation of the patients was by history, physical exam, and autophotography, and some patients had duplex ultrasound with vasoactive injection to measure curvature. Plaque size and pain were also assessed. Overall, the men receiving carnitine did better with respect to curvature than those who took tamoxifen with significantly fewer side effects. Unfortunately, curvature data were reported as mean deformity for the group with no indication as to the number of men responding or mean degree of improvement. Further evaluation of carnitine in combination with other therapies has been investigated and will be discussed later.
Intralesional therapy
Based upon anti-inflammatory properties, as well as decreased collagen synthesis by unclear mechanisms, steroids have been employed as an intralesional therapy for Peyronie's disease. In 1954, Tearsley 21 described the intralesional use of steroids in 29 poorly characterized patients with unclear results. Also in 1954, Bodner et al 22 reported good results of intralesional cortisone and hydrocortisone treatment in 17 patients. In 1975, Winter and Khanna 23 published their results on the use of mechanically aided injection (Dermo-Jet) of dexamethasone. They reported on 21 patients who were managed with 6-10 injections of 0.4% dexamethasone solution per treatment, repeated monthly for a total of 1-6 months. Although they noticed a decrease in both plaque size and pain during intercourse, no statistical difference was evident in comparison to the natural history of the disease. The authors also failed to quantify objectively the changes in plaque size and degree of the curvature.
In 1980, Williams and Green 24 described a prospective study on the use of intralesional triamcinolone, a long-acting glucocorticoid with low solubility, which theoretically produces maximal local action with minimal systemic side effects. A total of 45 patients were followed for 1 y without treatment and then treated with intralesional triamcinolone hexacetonide at 6-weekly intervals for 36 weeks. During the 1 y observation period, only three patients (6%) had spontaneous resolution of their symptoms. After the initiation of therapy, 33% of the patients noticed marked improvement. The mean duration of treatment that resulted in clinical improvement was 18 weeks. Pain, when present, improved first and most consistently, followed by plaque and then curvature. They also identified that patients under the age of 50 with small, firm, discrete plaques are more likely to respond to triamcinolone treatment.
We now recommend that treatment of Peyronie's disease with intralesional steroids be eliminated or at least initiated with extreme caution because of local side effects and the inconsistent pattern of improvement in well-established curvature. Although steroids are known to suppress fibroblast production of collagen, this effect is unpredictable and may result in local tissue atrophy. Anecdotally, in one unreported case, a patient developed adrenal insufficiency due to excessive use of steroid injections. In addition, steroid injections make surgery more complex due to the difficulty in subsequent separation of tissue planes between Buck's fascia and the tunica albuginea.
Purified clostridial collagenase was first studied in vitro with surgically excised Peyronie's plaques by Gelbard et al 25 27 In this study of 49 men, a statistically significant improvement in plaque size was found following collagenase treatment as compared to placebo control. The patients were stratified according to the severity of their disease and a modified Kelami system was used for classification. 28 Category 1 patients had a bend of 301 or less, and/or a palpable plaque of less than 2 cm. Category 2 patients displayed 30-601 of angulation and/or a palpable plaque between 2 and 4 cm. Category 3 patients had greater than 601 penile bending and/or greater than a 4 cm plaque. The researchers used vacuum chamber photography to document the degree of angulation. The category 1 patients responded best to the treatment (three of three (100%) who received the study drug noted some improvement), followed by category 2 (36%), and category 3 (13%). The authors cautioned, though, that maximal angular improvement observed ranged from 15 to 201, which was noted only in category 1 patients. In more severe cases, change in curvature was detectable but not clinically significant. No side effects were noted by the authors. This mode of therapy may have promise as an option for mild to moderate degrees of Peyronie's disease and will need further evaluation in a larger scale placebo-controlled multicenter study.
The calcium antagonist verapamil was first reported as an intralesional therapy by Levine et al 29 in 1994. The rationale for use of verapamil comes from the experiments by Kelly, 30 who in 1985 demonstrated that exocytosis of extracellular matrix molecules including collagen, fibronectin, and glycosaminoglycans, the primary components of a Peyronie's plaque, is a calcium ion-dependent process. Aggeler et al 31 demonstrated that when fibroblasts were exposed to antitubular agents and calcium antagonists in vitro, a change in cell shape was noted. This morphogenic change resulted in an altered protein secretion phenotype, manifested by increased extracellular matrix collagenase secretion as well as decreased collagen and fibronectin synthesis and secretion. 31 Similar changes have been seen when fibroblasts have been exposed in vitro to other agents such as colchicine, tamoxifen, and interferon. Lee and Ping 32 reported in 1990 on their experiments with cultured bovine fibroblasts exposed to increasing concentrations of verapamil and nifedipine. They found a dose-dependent decrease in the incorporation of radiolabeled proline and sulfate into extracellular matrix collagen and glycosaminoglycans, respectively, indicating decreased synthesis and secretion of these cellular products. They also noted that the doses necessary to inhibit extracellular matrix formation are much greater than the typical doses in systemic use of these drugs for hypertension. Therefore, local injections of verapamil were necessary to avoid systemic toxicity and to expose fibroblasts within the plaque to an adequate verapamil concentration.
In the first noncontrolled, nonrandomized study of intralesional verapamil for Peyronie's disease, 14 men with a mean age of 51 y received this therapy in a dose-escalating fashion. 29 The starting concentration was 1 mM and was doubled monthly. All patients received 12 injections over 6 months with a maximum dose of 10 mg in 10 ml of solution. In all, 91% of patients who had experienced pain at the initiation of the study had rapid resolution of the pain within 1-2 injections. Penile deformity, including shaft narrowing, decreased in 100% of patients, but curvature improved in only 42%. A total of 58% reported that their sexual performance had improved. Overall, 83% noted that the disease had arrested or improved with no recurrence of symptoms of deformity within an 8-month followup period.
More recent research has also demonstrated the effects of verapamil to modulate extracellular matrix metabolism by inhibiting the secretion of collagen as well as by increasing the proteolytic activity of collagenase, thereby enhancing matrix remodeling by human fibroblasts in burn scars and vascular smooth muscle cells in vitro. 33, 34 An in vitro study examining the effects of biologic modifiers on fibroblasts derived from Peyronie's plaques demonstrated that verapamil inhibited the proliferation of these cells more than interferon alpha-2b, colchicine, and prostaglandin E. 35 In addition, verapamil and other calcium channel blockers were found to affect cytokine expression associated with early phases of wound healing and inflammation, including platelet-derived growth factor-BB, interleukin-6, and interleukin-8. 34, 36 All this work indicated the importance of regulating the balance between matrix biosynthesis and degradation by fibroblasts.
Further published studies on the use of verapamil for Peyronie's disease include a report by Teloken et al, 37 who noted no advantage to verapamil over placebo or steroids when given in a controlled fashion. Yet, the study agents were not injected into the plaque; rather, they were injected around the plaque. It seems that if a change in fibroblast metabolism and plaque behavior is expected, a more concentrated direct distribution of drug is necessary. Rehman et al 38 in a randomized single-blind trial of intralesional verapamil vs saline reported on 14 patients in which there was a decreased plaque volume of 57% in the verapamil group vs 28% in the control group, a nonsignificant improvement trend in penile curvature in the verapamil group of 38 vs 301 in the control group, and a subjective improvement in penile narrowing in all verapamil patients with improved quality of erection in 43% vs none in the control group.
Recently, Levine et al 39 published their results on 156 consecutive men treated with intralesional verapamil. The treatment technique was reported in this nonrandomized trial and is worth repeating as proper technique seems to enhance success. A volume of 10-20 cm 3 of 0.5% bupivacine without epinephrine is injected as a penile block. Following adequate anesthesia, a multiple puncture technique is used into the plaque where a single puncture is made through the skin with multiple passes through the plaque in an effort to leave the drug behind in the needle tracks. No effort is made to 'disrupt the plaque' with the needle. A short (5/8 inch) 25-gauge or larger caliber needle is recommended to prevent inadvertent breakage of the needle. The standard dose based upon previous studies is 10 mg of verapamil diluted with 6 cm 3 of injectable saline for a total volume of 10 cm 3 . Injections are made no more frequently than every 2 weeks for a total of 12 injections. Following injection, the site is compressed for 5 min and blood pressure is monitored at 5-10 min. Of note is the fact that with over 400 men treated, there have been no cardiovascular side effects. If no improvement is noted by the patient with respect to deformity, after six injections, it is recommended to discontinue the verapamil injection therapy.
In this study, the mean age was 51 y, 77.5% of patients had failed prior oral therapy with vitamin E, colchicine, and/or Potaba. Disease duration averaged 18 months with a range of 1-96 months, 56% of patients had pain at presentation, 46% had narrowing with hinge affect, and distal softening was noted in 37%. Subjective results reported by the patients in the 128 men who completed the study revealed that 84% of men with pain had resolution; curvature improved in 62% with a mean improvement of 311 (range 5-751). Interestingly, improvement of girth was noted in 83% of men overall, many of whom did not complain of shaft narrowing at presentation. Rigidity was also reported subjectively to be better in 80% and sexual performance improved in 71%. Objective results were measured by duplex ultrasound using a vasoactive agent (papaverine 30-90 mg) to create a full erection by a blinded technician. Duplex vascular flow parameters did not change; 60% of men were noted with a mean curvature improvement of 301 (range 5-751). A total of 8% were noted to get worse with a The potential use of interferons as an intralesional therapy for Peyronie's disease was demonstrated in a 1991 study by Duncan et al 40 in which fibroblasts from Peyronie's plaques were cultured in the presence of interferons alpha-2b, beta ser17, and gamma. The rationale for interferon therapy originates from studies illustrating similar fibroblast activity in Peyronie's plaque, keloid scars, and scleroderma. 41, 42 In these disorders, fibroblasts are activated and produce excessive amounts of extracellular matrix components, including collagen, glycosaminoglycans, and fibronectin. In fibroblasts derived from Peyronie's plaques, the addition of interferons decreased the rate of proliferation in a dose-dependent fashion, decreased the production of extracellular collagen, and increased the production of collagenase. These in vitro results suggest the potential of interferons as an in vivo treatment for Peyronie's disease.
Several clinical trials of intralesional interferon for Peyronie's disease have been published. Wegner et al 43 studied 25 men who were given five local injections of 1 million units of interferon-alpha-2b on a weekly basis. The condition improved clinically in only one case. Side effects, including myalgia and fever, occurred in four (16%) patients.
Further dose-finding studies by Wegner et al 44 in 30 patients with 3 million units IFN-alpha 2b given weekly for three injections demonstrated clinical improvement in only one subject. Three worsened and 10 new plaques developed. A total of 25% of patients had intolerable side effects, including 74 of 90 injections causing fever 4381C. They concluded that this agent is not useful for the treatment of Peyronie's disease with this regimen. Using a different dosing regimen with IFN-alpha 2b of 1.5 million units three times a week for 3 weeks, Judge and Wisniewski 45 reported on 10 patients again treated without a control arm. Six of 10 had disappearance of pain and subjective improvement in deformity. Objective improvement in deformity was considered small with mean improvement of 201. Patients with small plaques (o4 cm) were more likely to have a better response. All patients experienced brief influenza side effects.
Interest in intralesional interferon therapy was recently revived by a noncontrolled trial by Ahuja et al. 46 In this study, 20 men with Peyronie's disease received 1 million units every 2 weeks for 6 months. In this study group, softening of the plaque was noted in 100%, 90% of the men who presented with pain had improvement, subjectively 55% had reduction in curvature, and 85% had an objectively measured reduction in plaque size. At this time, a multicenter placebo-controlled industry supported placebo trial is ongoing.
Topical therapy
At least two topical verapamil creams have been available for several years by prescription. They are a patented formulation produced in compounding pharmacies, but not FDA approved. There have been no published placebo-control trials in the peerreviewed literature. Yet, several presentations at national and international meetings have reported remarkably high response rates with respect to diminished pain, plaque size, and deformity as well as improved sexual function overall. The most recent study examining topical verapamil cream was by Martin et al. 47 In this study, patients who were undergoing penile prosthesis placement had application of the commercially available verapamil cream to the penile shaft. The drug was maintained on the shaft of the penis for a minimum of 12 h following which surgery was performed. The tunica albuginea was then assessed for verapamil. No verapamil was detected in any of the tunica specimens examined. As a result of this study and the lack of a controlled trial, topical verapamil cream therapy is not recommended.
External energy therapy
Multiple reports have been presented at international meetings, over the past several years, describing therapy for Peyronie's disease using various energy modalities alone or in combination with agents, including steroids, verapamil, and orgotein. In an Italian study of 68 patients receiving orgotein infiltration with or without topical laser and ultrasound therapy, pain was noted to resolve rapidly, but there was no improvement of penile bending. 48 Two nonrandomized trials examined the efficacy of topically applied verapamil with enhanced penetration using iontophoresis. In the first study by Reidl et al, 49 100 men received a combination of verapamil, dexamethasone, and lidocaine delivered with an energy of 2 milliamperes (mA) weekly from 3 to 53 weeks. A total of 96% of patients noted a reduction in pain, 53% a reduction in plaque size, and subjective improvement of curvature was reported in 37% with 16% of patients noting complete or greater than 301 of improvement. Erectile dysfunction was reported as improved in 44% and there was a 15% recurrence rate with a short follow-up period of 5.5 months. In a separate noncontrolled trial by Montorsi et al, 50 25 men received verapamil and dexamethasone at 2 mA three times a week for 3 weeks. Rigidity was noted to be improved subjectively in 80%, curvature was reduced in 88%, yet the degree of improvement was not reported. The conclusion by the authors was that this form of iontophoresis known as electromotive drug administration (EMDA) 'may lessen the need for surgery'. In a 2002 study by Levine et al, 16 men underwent surgical correction of their Peyronie's disease. Prior to incision, EMDA was performed with 10 mg of verapamil alone for 20 min at 2 mA power. 51 The excised tunica under the EMDA treatment area was evaluated for verapamil content by liquid chromography-tandem mass spectrometry. Verapamil was found in 73% of tunica specimens at varying levels ranging from 0.5 to 30% of the direct level measured following direct plaque injection of verapamil. As a result of this trial, there is an ongoing placebo-controlled study of verapamil vs saline using EMDA at Rush Medical Center in Chicago.
Local penile electroshock wave therapy (ESWT) has also been reported in several studies as topical therapy for Peyronie's disease. [52] [53] [54] [55] The rationale for this approach is not yet known, but has been suggested to have several possible mechanisms including (1) direct damage to the plaque resulting in an inflammatory reaction with increased macrophage activity yielding plaque lysis, (2) as a result of changes in plaque configuration and inflammatory response following ESWT, there may be improved vascularity with plaque resorption, and (3) repeated trauma to the area of plaque and deformity results in a contralateral scarring, which may shorten the contralateral side and result in a false straightening of the penis. There have been limited studies on ESWT to soft tissue. In one pigskin study, ESWT appeared to stimulate wound healing by unknown mechanisms, and in a histologic study of rabbit penile tissues subjected to shock waves, no histological changes were noted. 56 Although there have been many published abstracts demonstrating the benefits of ESWT for Peyronie's disease, relatively few have been published in the peer reviewed literature, all of which are noncontrolled and compromised by subjective reports of improvement of deformity, plaque size, or pain. In addition, objective measures are limited to autophotography performed by the patient before and after treatment. 57 These studies showed mean improvement in deformity of 10-311 in 28-53.7% of men treated. Mean curvature improvement by degree was not reported in most of the published studies, but was noted to be 10-311 in two studies. Pain improved in 77-100%, overall general improvement was reported in 0-72%, and coitus was reported enhanced in 20-62% of patients. The study by Hauck et al 55 attempted to approximate a placebo-controlled trial. In this study, 20 men underwent ESWT vs 23 who received an oral placebo for 6 months. Success was defined as a reduction of curvature greater than 30%
(not degrees). Patients received 2000 shocks on two occasions, which was repeated again in 3 months. When comparing the two groups, the authors concluded that ESWT showed no significant effect when the duration of the disease was greater than 1 y or the patient had failed prior oral treatment. There was also no significant change with respect to plaque size or curvature reduction of 101 or more. Subjective improvement was also assessed and there was no benefit with respect to quality of coitus, rigidity, and overall improvement of sexual function in the ESWT group.
The most common device used during penile ESWT was the Storz Minilith device, which employs ultrasound to localize the plaque. Manikandan et al 53 recently demonstrated successful plaque identification for ESWT using X-ray technology following subcutaneous injection of 1 cm 3 of a radiodense solution over the area of plaque.
Combination therapy
Combination medical therapy is designed to take advantage of the benefits of the various treatments working on different pathways to enhance improvement of penile deformity and subsequent sexual function. Mirone et al 58 examined 130 men with Peyronie's disease in a prospective trial. In this study, it appears that the only measured outcome parameter was ultrasound plaque size change. Two groups were examined. In those who received ESWT only, 52% were noted with smaller plaques. In the second group who received shock waves plus perilesional verapamil injections, 19% were improved. In a subsequent trial by the same group, 481 men were enrolled in a prospective trial where again plaque size change by ultrasound measurement was the primary parameter of success. 59 In the first group where only shock waves were used, 49% were noted with a smaller plaque. In the second group where shock waves plus perilesional verapamil injections were used in 324 patients, 49% noticed a smaller plaque and in the group that received verapamil injections alone, 101 patients were treated and 40% had a smaller plaque. The conclusion by this group was that ESWT plus verapamil injections are the recommended nonsurgical treatment of choice.
Another form of combination therapy was reported by Cavallini et al 20 in a study of 60 men who were randomized to receive intralesional verapamil (10 mg weekly for 10 weeks), plus oral propionyl-lcarnitine (2 g daily for 3 months) vs intralesional verapamil plus oral tamoxifen (40 mg daily for 3 months). In this study, there was no significant difference in pain reduction between the two groups, but the combination of verapamil and carnitine demonstrated significant subjective improvement in curvature, plaque size, and diastolic flow velocity on duplex ultrasound as well as IIEF results. The concept of combination therapy acting on different aspects of the disordered wound healing process found in men with Peyronie's disease makes sense and may increase the likelihood of positive results.
Clearly, the need for continued controlled clinical trials is in order as well as basic research into the pathophysiology of this disorder. Breakthroughs in understanding the role of cytokines and fibroblast activity as well as their interaction with extracellular matrix macromolecules, including collagen but likely other components, will enhance our ability to offer reasonable and effective nonsurgical therapy. In addition, further investigation will be necessary to establish standards for evaluating subjective and objective measures of sexual function, plaque, and deformity change. Efforts to establish a standardized approach for evaluation of the man with Peyronie's disease are ongoing and will hopefully provide uniform guidelines for reporting outcomes of trials of treatment for this difficult problem worldwide.
